NAGIOS: RODERIC FUNCIONANDO

A multicenter observational study on Medication-Related Osteonecrosis of the Jaw (MRONJ) in advanced cancer and myeloma patients of a cancer network in North-Western Italy

Repositori DSpace/Manakin

IMPORTANT: Aquest repositori està en una versió antiga des del 3/12/2023. La nova instal.lació está en https://roderic.uv.es/

A multicenter observational study on Medication-Related Osteonecrosis of the Jaw (MRONJ) in advanced cancer and myeloma patients of a cancer network in North-Western Italy

dc.contributor.author	Fusco, Vittorio	es
dc.contributor.author	Cabras, Marco	es
dc.contributor.author	Erovigni, Francesco	es
dc.contributor.author	Dell?Acqua, Alessandro	es
dc.contributor.author	Arduino, Paolo-Giacomo	es
dc.contributor.author	Pentenero, Monica	es
dc.contributor.author	Appendino, Paolo	es
dc.contributor.author	Basano, Lorenzo	es
dc.contributor.author	Ferrera, Francesco Della	es
dc.contributor.author	Fasciolo, Antonella	es
dc.contributor.author	Caka, Majlinda	es
dc.contributor.author	Migliario, Mario	es
dc.contributor.author	Franchi, Stefano	es
dc.contributor.author	Gambino, Alessio	es
dc.date.accessioned	2023-06-16T08:36:41Z
dc.date.available	2023-06-16T08:36:41Z
dc.date.issued	2021	es
dc.identifier.citation	Fusco, V., Cabras, M., Erovigni, F., Dell’Acqua, A., Arduino, PG., Pentenero, M., Appendino, P., Basano, L., Ferrera, FD., Fasciolo, A., Caka, A., & Migliario, M. (2021). A multicenter observational study on Medication-Related Osteonecrosis of the Jaw (MRONJ) in advanced cancer and myeloma patients of a cancer network in North-Western Italy. En Medicina Oral Patología Oral y Cirugia Bucal (pp. e466-e473). Medicina Oral, S.L. https://doi.org/10.4317/medoral.24318	es
dc.identifier.uri	https://hdl.handle.net/10550/88047
dc.description.abstract	Incidence of Medication-Related Osteonecrosis of the Jaw (MRONJ) related to cancer and myeloma treatments is undetermined, with scarce data varying from 2 to 7.8/million/year in limited investigated populations. A 9-years [2009-2018] regional-wide survey was conducted, deploying the North-Western Italy Cancer Network (?Rete Oncologica Piemonte e Valle d?Aosta?), to assess number and main characteristics of MRONJ cases among myeloma/cancer patients, within a population of 4.5 million inhabitants. MRONJ cases were collected retrospectively from January 2009 to June 2015; from July 2015 to December 2018, data were collected prospectively. Number of new MRONJ cases per year, underlying disorder, drug(s) administered, treatment duration, site and onset timing of MRONJ were detailed. 459 MRONJ cases were identified. Primary diseases were breast cancer (46%), prostate cancer (21%), myeloma (19%), and other types of carcinoma (14%). Patients received antiresorptive treatment either alone (399; 88.47%) or in combination with biological agents (52; 11.53%); 8 patients (1.7%) received only antiangiogenic drugs. Zoledronic acid [388] and denosumab [59] were the most frequently administered drugs. Mandible was involved in 296 (64,5%) cases. Number of new MRONJ cases was stable from 2009 to 2015, with a mean of 51.3 cases per year (raw incidence: 11.6/million/year), declining in the 2016-2018 years to 33.3 cases per year (raw incidence: 7.5/million/year). With such discrepancy of cases overtime being partially explicable, number of new MRONJ cases per year are consistent with those observed in a previous study [2003-2008] in the same region, being instead higher than those reported in other populations.	es
dc.subject	buccal fat pad	es
dc.subject	buccal fat pad excision	es
dc.subject	surgery	es
dc.subject	plastic	es
dc.subject	aesthetics	es
dc.subject	cheek refinement	es
dc.subject	facial silhouette refining	es
dc.title	A multicenter observational study on Medication-Related Osteonecrosis of the Jaw (MRONJ) in advanced cancer and myeloma patients of a cancer network in North-Western Italy	es
dc.type	journal article	es_ES
dc.subject.unesco	UNESCO:CIENCIAS MÉDICAS	es
dc.identifier.doi	10.4317/medoral.24318	es
dc.type.hasVersion	VoR	es_ES
dc.identifier.url	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8254890/